Wesnes K

General

Full name : Wesnes Keith

First name : Keith

Mail : United BioSource Corporation, Goring-on-Thames

Zip Code :

City :

Country : United Kingdom

Email :

Phone :

Fax :

Website :

Directory :

References (9)

Title : Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease - Rinne_2017_Alzheimers.Dement.(N.Y)_3_1
Author(s) : Rinne JO , Wesnes K , Cummings JL , Hakulinen P , Hallikainen M , Hanninen J , Murphy M , Riordan H , Scheinin M , Soininen H , Rouru J
Ref : Alzheimers Dement (N Y) , 3 :1 , 2017
Abstract :
PubMedSearch : Rinne_2017_Alzheimers.Dement.(N.Y)_3_1
PubMedID: 29067315

Title : The scopolamine model as a pharmacodynamic marker in early drug development - Lenz_2012_Psychopharmacology.(Berl)_220_97
Author(s) : Lenz RA , Baker JD , Locke C , Rueter LE , Mohler EG , Wesnes K , Abi-Saab WM , Saltarelli MD
Ref : Psychopharmacology (Berl) , 220 :97 , 2012
Abstract :
PubMedSearch : Lenz_2012_Psychopharmacology.(Berl)_220_97
PubMedID: 21901320

Title : Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease - Wesnes_2010_Acta.Neurol.Scand_122_270
Author(s) : Wesnes K , Edgar C , Andreasen N , Annas P , Basun H , Lannfelt L , Zetterberg H , Blennow K , Minthon L
Ref : Acta Neurologica Scandinavica , 122 :270 , 2010
Abstract :
PubMedSearch : Wesnes_2010_Acta.Neurol.Scand_122_270
PubMedID: 20047570

Title : Effects of galantamine on measures of attention: results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil - Galvin_2008_Alzheimer.Dis.Assoc.Disord_22_30
Author(s) : Galvin JE , Cornblatt B , Newhouse P , Ancoli-Israel S , Wesnes K , Williamson D , Zhu Y , Sorra K , Amatniek J
Ref : Alzheimer Disease & Associated Disorders , 22 :30 , 2008
Abstract :
PubMedSearch : Galvin_2008_Alzheimer.Dis.Assoc.Disord_22_30
PubMedID: 18317244

Title : Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies - Rowan_2007_Dement.Geriatr.Cogn.Disord_23_161
Author(s) : Rowan E , McKeith IG , Saxby BK , O'Brien JT , Burn D , Mosimann U , Newby J , Daniel S , Sanders J , Wesnes K
Ref : Dementia & Geriatric Cognitive Disorders , 23 :161 , 2007
Abstract :
PubMedSearch : Rowan_2007_Dement.Geriatr.Cogn.Disord_23_161
PubMedID: 17192712

Title : Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers - Dunbar_2007_Psychopharmacology.(Berl)_191_919
Author(s) : Dunbar GC , Boeijinga PH , Demazieres A , Cisterni C , Kuchibhatla R , Wesnes K , Luthringer R
Ref : Psychopharmacology (Berl) , 191 :919 , 2007
Abstract :
PubMedSearch : Dunbar_2007_Psychopharmacology.(Berl)_191_919
PubMedID: 17225162

Title : Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease - Vellas_2005_Curr.Med.Res.Opin_21_1423
Author(s) : Vellas B , Cunha L , Gertz HJ , De Deyn PP , Wesnes K , Hammond G , Schwalen S
Ref : Curr Med Res Opin , 21 :1423 , 2005
Abstract :
PubMedSearch : Vellas_2005_Curr.Med.Res.Opin_21_1423
PubMedID: 16197661

Title : Regulation of attention and response to therapy in dementia by butyrylcholinesterase - O'Brien_2003_Pharmacogenet_13_231
Author(s) : O'Brien KK , Saxby BK , Ballard CG , Grace J , Harrington F , Ford GA , O'Brien JT , Swan AG , Fairbairn AF , Wesnes K , Del Ser T , Edwardson JA , Morris CM , McKeith IG
Ref : Pharmacogenetics , 13 :231 , 2003
Abstract :
PubMedSearch : O'Brien_2003_Pharmacogenet_13_231
PubMedID: 12668920

Title : Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study - McKeith_2000_Lancet_356_2031
Author(s) : McKeith I , Del Ser T , Spano P , Emre M , Wesnes K , Anand R , Cicin-Sain A , Ferrara R , Spiegel R
Ref : Lancet , 356 :2031 , 2000
Abstract :
PubMedSearch : McKeith_2000_Lancet_356_2031
PubMedID: 11145488